The Omicron mutation is causing a lot of breakthrough infections in both vaccinated and previously recovered patients, and while the variant is not especially lethal for young people, it is still dangerous to the elderly and immunocompromised.
The only worthwhile antibody treatment in the US, the Regeneron cocktail, doesn’t work against Omicron. AstraZeneca’s cocktail does appear to work, but it is scarce and not approved in the US.
That makes prompt deployment of the anti-viral Paxlovid vital if we are to avoid a catastrophic outbreak next month. Paxlovid is a protease inhibitor and is not affected by the mutations to the spike protein.
Already, COVID has killed 1 out of every 100 Americans over 65, and if the FDA keeps dragging its feet, the Social Security shortfall problem will be solved by spring.